BRPI0406737A - Formulações parenterais de um peptìdeo para o tratamento de eritomatose sistêmica de lupus - Google Patents
Formulações parenterais de um peptìdeo para o tratamento de eritomatose sistêmica de lupusInfo
- Publication number
- BRPI0406737A BRPI0406737A BR0406737-1A BRPI0406737A BRPI0406737A BR PI0406737 A BRPI0406737 A BR PI0406737A BR PI0406737 A BRPI0406737 A BR PI0406737A BR PI0406737 A BRPI0406737 A BR PI0406737A
- Authority
- BR
- Brazil
- Prior art keywords
- peptide
- systemic lupus
- treatment
- composition
- lupus erythematosis
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 title 1
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 229920000858 Cyclodextrin Polymers 0.000 abstract 1
- JVZLZVJTIXVIHK-SXNHZJKMSA-N Glu-Trp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CCC(=O)O)N JVZLZVJTIXVIHK-SXNHZJKMSA-N 0.000 abstract 1
- ASCFJMSGKUIRDU-ZPFDUUQYSA-N Ile-Arg-Gln Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(O)=O ASCFJMSGKUIRDU-ZPFDUUQYSA-N 0.000 abstract 1
- LCMWVZLBCUVDAZ-IUCAKERBSA-N Lys-Gly-Glu Chemical compound [NH3+]CCCC[C@H]([NH3+])C(=O)NCC(=O)N[C@H](C([O-])=O)CCC([O-])=O LCMWVZLBCUVDAZ-IUCAKERBSA-N 0.000 abstract 1
- LEIKGVHQTKHOLM-IUCAKERBSA-N Pro-Pro-Gly Chemical compound OC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 LEIKGVHQTKHOLM-IUCAKERBSA-N 0.000 abstract 1
- HWCBFXAWVTXXHZ-NYVOZVTQSA-N Trp-Ser-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)O)N HWCBFXAWVTXXHZ-NYVOZVTQSA-N 0.000 abstract 1
- KOSRFJWDECSPRO-UHFFFAOYSA-N alpha-L-glutamyl-L-glutamic acid Natural products OC(=O)CCC(N)C(=O)NC(CCC(O)=O)C(O)=O KOSRFJWDECSPRO-UHFFFAOYSA-N 0.000 abstract 1
- 239000008365 aqueous carrier Substances 0.000 abstract 1
- 239000008135 aqueous vehicle Substances 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 108010055341 glutamyl-glutamic acid Proteins 0.000 abstract 1
- 206010025135 lupus erythematosus Diseases 0.000 abstract 1
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 230000009885 systemic effect Effects 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Transplantation (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
"FORMULAçõES PARENTERAIS DE UM PEPTìDEO PARA O TRATAMENTO DE ERITOMATOSE SISTêMICA DE LUPUS". A presente invenção prove uma composição farmacêutica compreendendo um veículo aquoso; de 0,1 mg/ml a 20 mg/ml da composição de um sal farmaceuticamente aceitável de um peptídeo possuindo a fórmula estrutural NH~ 2~-Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu Trp Ile Gly-COOH; e uma 13-ciclodextrina substituída em uma quantidade efetiva para dissolver o peptídeo no veículo aquoso, onde a composição possui um pH entre 4 e 9, um processo para preparação, e um método de aliviar sintomas de eritomatose sistêmica de lupus (SLE) em um indivíduo humano compreendendo administrar ao indivíduo humano a composição farmacêutica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43995003P | 2003-01-14 | 2003-01-14 | |
| PCT/US2004/000955 WO2004064788A2 (en) | 2003-01-14 | 2004-01-14 | Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0406737A true BRPI0406737A (pt) | 2005-12-20 |
Family
ID=32771763
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0406737-1A BRPI0406737A (pt) | 2003-01-14 | 2004-01-14 | Formulações parenterais de um peptìdeo para o tratamento de eritomatose sistêmica de lupus |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US7294687B2 (pt) |
| EP (1) | EP1587525A4 (pt) |
| JP (1) | JP2006516034A (pt) |
| KR (1) | KR20050100616A (pt) |
| CN (1) | CN1761477A (pt) |
| AU (1) | AU2004206844A1 (pt) |
| BR (1) | BRPI0406737A (pt) |
| CA (1) | CA2513331A1 (pt) |
| CO (1) | CO5640149A2 (pt) |
| CR (1) | CR7936A (pt) |
| EA (1) | EA008438B1 (pt) |
| EC (1) | ECSP055960A (pt) |
| MX (1) | MXPA05007552A (pt) |
| NO (1) | NO20053761L (pt) |
| NZ (1) | NZ541659A (pt) |
| UA (1) | UA83816C2 (pt) |
| WO (1) | WO2004064788A2 (pt) |
| ZA (1) | ZA200506205B (pt) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL141647A0 (en) | 2001-02-26 | 2002-03-10 | Yeda Res & Dev | Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
| KR20050100617A (ko) * | 2003-01-14 | 2005-10-19 | 테바 파마슈티컬 인더스트리즈 리미티드 | 전신 홍반 루푸스 치료용 펩티드의 비 경구 제형 |
| JP2006516034A (ja) * | 2003-01-14 | 2006-06-15 | テバ ファーマシューティカル インダストリーズ リミティド | 全身性エリテマトーデスを治療するためのペプチドの非経口製剤 |
| DE102004043750A1 (de) * | 2004-09-10 | 2006-03-30 | Sanofi-Aventis Deutschland Gmbh | Formulierungen des Peptids p277 oder dessen Varianten mit optimierter Stabilität |
| US20100160442A1 (en) * | 2006-07-18 | 2010-06-24 | Ossovskaya Valeria S | Formulations for cancer treatment |
| WO2008073448A2 (en) * | 2006-12-12 | 2008-06-19 | Amylin Pharmaceuticals, Inc. | Pharmaceutical formulations and methods for making the same |
| EP2121139B1 (en) * | 2007-01-16 | 2012-10-10 | BiPar Sciences, Inc. | Formulations for cancer treatment |
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| MX2011000847A (es) | 2008-08-06 | 2011-02-25 | Novo Nordisk Healthcare Ag | Proteinas conjugadas con eficacia prolongada in vivo. |
| WO2013123254A1 (en) | 2012-02-15 | 2013-08-22 | Cydex Pharmaceuticals, Inc. | Manufacturing process for cyclodextrin derivatives |
| KR102112119B1 (ko) | 2012-10-22 | 2020-05-19 | 사이덱스 파마슈티칼스, 인크. | 알킬화된 시클로덱스트린 조성물 및 이의 제조 및 사용 방법 |
| PT3183295T (pt) | 2014-08-22 | 2023-11-03 | Cydex Pharmaceuticals Inc | Composições de ciclodextrina alquilada fracionada e processos para preparação e utilização das mesmas |
| CA3047706A1 (en) | 2017-01-05 | 2018-07-12 | Yeda Research And Development Co. Ltd. | Peptides for treating sjogren's syndrome |
| CN110960442B (zh) * | 2019-12-17 | 2023-03-31 | 珠海冀百康生物科技有限公司 | 一种多肽包封物的制备方法 |
| EP4297727A4 (en) * | 2021-02-24 | 2024-12-25 | NBO Pharma Inc. | METHODS AND THERAPEUTIC COMBINATIONS FOR THE TREATMENT OF IDIOPATHIC INTRACRANIAL HYPERTENSION AND FACIAL PAIN |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60184098A (ja) * | 1984-03-02 | 1985-09-19 | Suntory Ltd | 新規なペプチド及びこれを有効成分とする利尿剤 |
| US6407079B1 (en) * | 1985-07-03 | 2002-06-18 | Janssen Pharmaceutica N.V. | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
| US5997856A (en) * | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
| US5126249A (en) | 1989-05-09 | 1992-06-30 | Eli Lilly And Company | Enzymatic removal of a protein amino-terminal sequence |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9017008D0 (en) | 1990-08-02 | 1990-09-19 | Erba Carlo Spa | Process for the enzymatic preparation of basic fibroblast growth factor |
| US5646131A (en) * | 1994-02-22 | 1997-07-08 | The Arab Company For Drug Industries And Medical Applicances (Acdima) | Method for solubilizing drugs using cyclodextrins and carboxylic acids |
| IL113159A0 (en) * | 1995-03-28 | 1995-06-29 | Yeda Res & Dev | Synthetic peptides and pharmaceutical compositions comprising them |
| US6613536B1 (en) | 1995-03-28 | 2003-09-02 | Yeda Research And Development Co. Ltd. | Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
| US20020054872A1 (en) | 1997-03-20 | 2002-05-09 | Yaakov Naparstek | Peptides for the treatment of systemic lupus erythematosus and methods of treating systemic lupus erythematosus |
| IL120503A0 (en) | 1997-03-20 | 1997-07-13 | Hadasit Med Res Service | Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them |
| WO1999031066A1 (en) | 1997-12-18 | 1999-06-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pyridones as src family sh2 domain inhibitors |
| IL141647A0 (en) * | 2001-02-26 | 2002-03-10 | Yeda Res & Dev | Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus |
| US7114005B2 (en) | 2002-02-05 | 2006-09-26 | Cisco Technology, Inc. | Address hopping of packet-based communications |
| JP2006516034A (ja) * | 2003-01-14 | 2006-06-15 | テバ ファーマシューティカル インダストリーズ リミティド | 全身性エリテマトーデスを治療するためのペプチドの非経口製剤 |
| KR20050100617A (ko) * | 2003-01-14 | 2005-10-19 | 테바 파마슈티컬 인더스트리즈 리미티드 | 전신 홍반 루푸스 치료용 펩티드의 비 경구 제형 |
-
2004
- 2004-01-14 JP JP2006500958A patent/JP2006516034A/ja not_active Withdrawn
- 2004-01-14 CN CNA2004800069919A patent/CN1761477A/zh active Pending
- 2004-01-14 BR BR0406737-1A patent/BRPI0406737A/pt not_active IP Right Cessation
- 2004-01-14 US US10/758,572 patent/US7294687B2/en not_active Expired - Lifetime
- 2004-01-14 EP EP04702214A patent/EP1587525A4/en not_active Withdrawn
- 2004-01-14 MX MXPA05007552A patent/MXPA05007552A/es active IP Right Grant
- 2004-01-14 NZ NZ541659A patent/NZ541659A/en unknown
- 2004-01-14 EA EA200501129A patent/EA008438B1/ru not_active IP Right Cessation
- 2004-01-14 KR KR1020057013097A patent/KR20050100616A/ko not_active Withdrawn
- 2004-01-14 UA UAA200507998A patent/UA83816C2/ru unknown
- 2004-01-14 WO PCT/US2004/000955 patent/WO2004064788A2/en not_active Ceased
- 2004-01-14 AU AU2004206844A patent/AU2004206844A1/en not_active Abandoned
- 2004-01-14 CA CA002513331A patent/CA2513331A1/en not_active Abandoned
-
2005
- 2005-08-03 ZA ZA200506205A patent/ZA200506205B/en unknown
- 2005-08-08 NO NO20053761A patent/NO20053761L/no not_active Application Discontinuation
- 2005-08-09 CR CR7936A patent/CR7936A/es unknown
- 2005-08-10 CO CO05079319A patent/CO5640149A2/es not_active Application Discontinuation
- 2005-08-11 EC EC2005005960A patent/ECSP055960A/es unknown
-
2007
- 2007-11-12 US US11/985,068 patent/US20080287366A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20080287366A1 (en) | 2008-11-20 |
| ECSP055960A (es) | 2006-04-19 |
| MXPA05007552A (es) | 2006-05-19 |
| EA200501129A1 (ru) | 2006-02-24 |
| EA008438B1 (ru) | 2007-06-29 |
| CA2513331A1 (en) | 2004-08-05 |
| KR20050100616A (ko) | 2005-10-19 |
| ZA200506205B (en) | 2006-12-27 |
| UA83816C2 (ru) | 2008-08-26 |
| EP1587525A4 (en) | 2008-09-10 |
| AU2004206844A1 (en) | 2004-08-05 |
| NO20053761L (no) | 2005-10-12 |
| WO2004064788A3 (en) | 2005-03-24 |
| JP2006516034A (ja) | 2006-06-15 |
| NZ541659A (en) | 2007-05-31 |
| EP1587525A2 (en) | 2005-10-26 |
| CR7936A (es) | 2006-05-31 |
| NO20053761D0 (no) | 2005-08-08 |
| US7294687B2 (en) | 2007-11-13 |
| WO2004064788A2 (en) | 2004-08-05 |
| CO5640149A2 (es) | 2006-05-31 |
| US20040180059A1 (en) | 2004-09-16 |
| CN1761477A (zh) | 2006-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0406737A (pt) | Formulações parenterais de um peptìdeo para o tratamento de eritomatose sistêmica de lupus | |
| KR102923527B1 (ko) | 생체활성 분자 접합체, 이의 제조 방법 및 용도 | |
| US20110040072A1 (en) | Mono and di-substituted oxycodone compounds and compositions | |
| US20080090771A1 (en) | Abuse-resistant hydrocodone compounds, compositions and methods of using the same | |
| JP2009533459A (ja) | 共有結合する化合物の鎮痛作用の増強と、有害な副作用の減衰と、前記化合物の乱用の予防とのための組成物及び方法 | |
| CR7938A (es) | Formulaciones parenterales de peptidos para el tratamiento de lupus eritematoso sistemico | |
| US20080207668A1 (en) | Pharmaceutical compositions of hydromorphone for prevention of overdose or abuse | |
| US20200237926A1 (en) | pHLIP® targeted delivery of potent cytotoxic compounds | |
| US2662046A (en) | Parenteral amino acid solution | |
| EP1991248B1 (en) | Antidepressant prodrugs | |
| EP4262745B1 (en) | Pharmaceutical composition of glp-1/glp-2 dual agonists | |
| AU2001280052B2 (en) | Pharmaceutical composition comprising an analgesic peptide | |
| WO2007056263A3 (en) | Methods of treating cancer with high potency lipid-based platinum compound formulations administered intravenously | |
| RU2005140680A (ru) | Фармацевтическая композиция для фотодинамической терапии и способ лечения онкологического заболевания с ее использованием | |
| CN116392602B (zh) | 两亲性多肽载体及其应用 | |
| WO2004058303A3 (en) | Compositions of benzoquinolizine carboxylic acid antibiotic drugs | |
| WO2003092736A3 (en) | Peptide nucleic acid conjugates with transporter peptides | |
| US20080234206A1 (en) | Prodrugs of Phentermine | |
| JP2641742B2 (ja) | 新規ペプチド及び抗菌剤 | |
| JPH0262559B2 (pt) | ||
| KR102499473B1 (ko) | 여성 성기능장애를 치료하기 위한 신규한 펩타이드군 | |
| Brinkworth et al. | Host defence peptides from the skin glands of Australian amphibians. Caerulein neuropeptides and antimicrobial, anticancer, and nNOS inhibiting citropins from the glandular frog Litoria subglandulosa | |
| CN101305099A (zh) | 具有提高的生物利用度的t3和t4的前药 | |
| ZA200608865B (en) | Biologically active peptide VAPEEHPTLLTEAPLNPK derivatives | |
| West et al. | Progress in Medicinal Chemistry |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A, 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |